N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CONNOLLY, Stephen, EBDEN, Mark Richard, WILLIAMS, Andrew John, STEVEN, Alan Robert, TOMLIN, Paula Margaret, WALTERS, Iain Alastair Stewart, LANGER, Thomas, STEWART, Craig Robert
Format: Patent
Sprache:eng ; ita
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CONNOLLY, Stephen
EBDEN, Mark Richard
WILLIAMS, Andrew John
STEVEN, Alan Robert
TOMLIN, Paula Margaret
WALTERS, Iain Alastair Stewart
LANGER, Thomas
STEWART, Craig Robert
description There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_SMT202100173TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>SMT202100173TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_SMT202100173TT13</originalsourceid><addsrcrecordid>eNqNjLsKwjAUhrs4iPoOGRxa8EBv6BzbUxLMpaSnYFxEJE6igj6Ij2wEH8Dpv3380-RtIF1DmpZuVQ0ZVKsaWil86-zeb0fiBkrwKoYsmrSGTo3W2S2ag1ckpM1676SWrTRQRzA-ANNIwit-QPr2CAUMo-qs4ZFDxgfWCNR2FyfmsMGerGPatqPi0c2TyeV0fYbFT2fJskNqBITH_Riej9M53MLrOGgq87LI82JTERXVn9gH5LNBXA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR</title><source>esp@cenet</source><creator>CONNOLLY, Stephen ; EBDEN, Mark Richard ; WILLIAMS, Andrew John ; STEVEN, Alan Robert ; TOMLIN, Paula Margaret ; WALTERS, Iain Alastair Stewart ; LANGER, Thomas ; STEWART, Craig Robert</creator><creatorcontrib>CONNOLLY, Stephen ; EBDEN, Mark Richard ; WILLIAMS, Andrew John ; STEVEN, Alan Robert ; TOMLIN, Paula Margaret ; WALTERS, Iain Alastair Stewart ; LANGER, Thomas ; STEWART, Craig Robert</creatorcontrib><description>There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.</description><language>eng ; ita</language><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210507&amp;DB=EPODOC&amp;CC=SM&amp;NR=T202100173T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210507&amp;DB=EPODOC&amp;CC=SM&amp;NR=T202100173T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CONNOLLY, Stephen</creatorcontrib><creatorcontrib>EBDEN, Mark Richard</creatorcontrib><creatorcontrib>WILLIAMS, Andrew John</creatorcontrib><creatorcontrib>STEVEN, Alan Robert</creatorcontrib><creatorcontrib>TOMLIN, Paula Margaret</creatorcontrib><creatorcontrib>WALTERS, Iain Alastair Stewart</creatorcontrib><creatorcontrib>LANGER, Thomas</creatorcontrib><creatorcontrib>STEWART, Craig Robert</creatorcontrib><title>N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR</title><description>There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLsKwjAUhrs4iPoOGRxa8EBv6BzbUxLMpaSnYFxEJE6igj6Ij2wEH8Dpv3380-RtIF1DmpZuVQ0ZVKsaWil86-zeb0fiBkrwKoYsmrSGTo3W2S2ag1ckpM1676SWrTRQRzA-ANNIwit-QPr2CAUMo-qs4ZFDxgfWCNR2FyfmsMGerGPatqPi0c2TyeV0fYbFT2fJskNqBITH_Riej9M53MLrOGgq87LI82JTERXVn9gH5LNBXA</recordid><startdate>20210507</startdate><enddate>20210507</enddate><creator>CONNOLLY, Stephen</creator><creator>EBDEN, Mark Richard</creator><creator>WILLIAMS, Andrew John</creator><creator>STEVEN, Alan Robert</creator><creator>TOMLIN, Paula Margaret</creator><creator>WALTERS, Iain Alastair Stewart</creator><creator>LANGER, Thomas</creator><creator>STEWART, Craig Robert</creator><scope>EVB</scope></search><sort><creationdate>20210507</creationdate><title>N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR</title><author>CONNOLLY, Stephen ; EBDEN, Mark Richard ; WILLIAMS, Andrew John ; STEVEN, Alan Robert ; TOMLIN, Paula Margaret ; WALTERS, Iain Alastair Stewart ; LANGER, Thomas ; STEWART, Craig Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_SMT202100173TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; ita</language><creationdate>2021</creationdate><toplevel>online_resources</toplevel><creatorcontrib>CONNOLLY, Stephen</creatorcontrib><creatorcontrib>EBDEN, Mark Richard</creatorcontrib><creatorcontrib>WILLIAMS, Andrew John</creatorcontrib><creatorcontrib>STEVEN, Alan Robert</creatorcontrib><creatorcontrib>TOMLIN, Paula Margaret</creatorcontrib><creatorcontrib>WALTERS, Iain Alastair Stewart</creatorcontrib><creatorcontrib>LANGER, Thomas</creatorcontrib><creatorcontrib>STEWART, Craig Robert</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CONNOLLY, Stephen</au><au>EBDEN, Mark Richard</au><au>WILLIAMS, Andrew John</au><au>STEVEN, Alan Robert</au><au>TOMLIN, Paula Margaret</au><au>WALTERS, Iain Alastair Stewart</au><au>LANGER, Thomas</au><au>STEWART, Craig Robert</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR</title><date>2021-05-07</date><risdate>2021</risdate><abstract>There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; ita
recordid cdi_epo_espacenet_SMT202100173TT1
source esp@cenet
title N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A43%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CONNOLLY,%20Stephen&rft.date=2021-05-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ESMT202100173TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true